121 results on '"Vidor E"'
Search Results
2. Evaluation of the Persistence of Vaccine-Induced Protection with Human Vaccines
3. Serological Diagnosis of Leishmaniasis: On Detecting Infection as Well as Disease
4. The Nature and Consequences of Intra- and Inter-Vaccine Interference
5. Vaccination of Newborns against Hepatitis A in the Presence of Maternally Derived Antibodies
6. Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data
7. Hydrometallurgical processing of carbon steel EAF dust
8. Clinical use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in civilian trauma systems in the USA, 2019: a joint statement from the American College of Surgeons Committee on Trauma, the American College of Emergency Physicians, the National Association of Emergency Medical Services Physicians and the National Association of Emergency Medical Technicians
9. Clinical development of a new inactivated hepatitis a vaccine
10. Lack of Co-Transmission of Rickettsia conorii and Ehrlichia canis in Human Beings in the South of France
11. Clinical use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in civilian trauma systems in the USA, 2019: a joint statement from the American College of Surgeons Committee on Trauma, the American College of Emergency Physicians, the National Association of Emergency Medical Services Physicians and the National Association of Emergency Medical Technicians
12. Articulatory awareness in children with normal and deviant phonological development
13. Lack of co-transmission of Rickettsia conorii and Ehrlichia canis in human beings in the south of France
14. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines
15. Design of a process for improvement of phosphatidylglycerol-phosphatidylinositol transfer protein recovery from Aspergillus oryzae
16. Polio eradication – Incorporating IPV more broadly
17. Viability Damage on Aspergillus flavus Spores by an Antifungal Aerosol/Schädigung der Lebensfähigkeit von Aspergillus flavus-Sporen durch ein pilzhemmendes Aerosol
18. Aventis Pasteur Vaccines Containing Inactivated Hepatitis A Virus: A Compilation of Immunogenicity Data
19. Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine
20. The place of DTP/eIPV vaccine in routine pediatric vaccination
21. Un suivi de Leishmania infantum dans une cohorte de chiens dans une région endémique du sud de la France
22. L'ehrlichiose humaine en Tunisie. Etude préliminaire
23. Human pathogenicity of Ehrlichia canis
24. Serological evaluation of Ehrlichia canis infections in military dogs in Africa and Reunion Island
25. Identification of major Babesia divergens polypeptides that induce protection against homologous challenge in gerbils
26. Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM).
27. Viability Damage on Aspergillus flavus Spores by an Antifungal Aerosol/Schädigung der Lebensfähigkeit von Aspergillus flavus-Sporen durch ein pilzhemmendes Aerosol.
28. Does immunoglobulin interfere with the immunogenicity to Pasteur Merieux inactivated hepatitis A vaccine?
29. Vaccination against canine babesiosis: an overview of field observations
30. Biochimie du liquide hydatique(Echinococcus granulosus).Influence de la localisation sur la perméabilité des kystes
31. Lack of co-transmission of Rickettsia conoriiand Ehrlichia canisin human beings in the south of France
32. Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.
33. Hepatitis B surface antigen prevalence and the rates of mother-to-child transmission of hepatitis B virus after the introduction of infant vaccination programs in South East Asia and Western Pacific regions: a systematic review.
34. A combined DTaP-IPV vaccine (Tetraxim®/Tetravac®) used as school-entry booster: a review of more than 20 years of clinical and post-marketing experience.
35. Post-Marketing Surveillance of Tetravalent Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus (DTaP-IPV) Vaccine in South Korea, 2009 to 2015.
36. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa.
37. A drop of self-confidence program about urinary incontinence.
38. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
39. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.
40. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea.
41. Immunogenicity and Safety of a Liquid Hexavalent Vaccine in Indian Infants.
42. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools.
43. Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China.
44. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
45. Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience.
46. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines.
47. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.
48. Repertoire of antibodies against type 1 poliovirus in human sera.
49. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations.
50. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.